$AKTS News

Last published 2mo ago

2mo agoAKTSAktis Oncology to Present at Upcoming September Investor ConferencesGlobeNewswireBOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient
3mo agoAKTSAktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026GlobeNewswirePresented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling patients in
5mo agoAKTSAktis Oncology to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large
5mo agoAKTSAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsGlobeNewswireData to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic
6mo agoAKTSAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026GlobeNewswireAnnounced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC);
6mo agoAKTSAktis Oncology to Present at the BofA Securities Health Care ConferenceGlobeNewswireBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large
6mo agoAKTSAktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)GlobeNewswireClinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial strategy
6mo agoAKTS AVLNTwo River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCBBusiness WireTwo River, LLC ("Two River") and Vida Ventures ("Vida"), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics ("Candid"), a privately held clinical-stage
6mo agoAKTSAktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireAKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal
6mo agoAKTSAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of DirectorsGlobeNewswireBOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large
7mo agoAKTSAktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial ResultsGlobeNewswireProgressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in
8mo agoAKTSAktis Oncology to Present at Upcoming March Investor ConferencesGlobeNewswireBOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient
8mo agoAKTSAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein RadioconjugateGlobeNewswireU.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b
10mo agoAKTSAktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations,
10mo agoAKTS LLYVida Ventures Congratulates Aktis Oncology on Its Entry into the Public MarketsBusiness WireVida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis' largest shareholders; Helen Kim, Vida Senior Managing Director,
1y agoAKTSAkoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessGlobeNewswireCharlotte, NC, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF
1y agoAKTSAkoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessBusiness WireCommitted to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final Judgement and
2y agoAKTSAkoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 CustomerGlobeNewswireCharlotte, NC, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer Raises Production Commitments for XBAW RF filters from
2y agoAKTSAkoustis Announces Leadership TransitionGlobeNewswireCharlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an
2y agoAKTSAkoustis Secures $8 Million in Volume XBAW® Orders with Tier-1 CustomerGlobeNewswireTier-1 Customer to Utilize Multiple XBAW® Filters for Wi-Fi 6E and 7 Access PointsVolume Orders to Satisfy Customer's Demand Through Fiscal Year 2025 Charlotte, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Akoustis
2y agoAKTSAkoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 CarrierGlobeNewswireTier-1 Customer to Use Akoustis' Next-Generation 5.5 and 6.5 GHz Wi-Fi XBAW® Filters in Tri-Band 4x4 MIMO RouterSecured Wi-Fi 7 Filter Orders to Support Production Beginning in July 2024 Through March 2025
2y agoAKTSAkoustis Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireCharlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Completes Rollout of its XBAW® Design UpdatesGlobeNewswireCharlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Technologies, Inc. (AKTS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAKTSAkoustis Reports Third Quarter FY24 ResultsGlobeNewswireQ3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow
2y agoAKTSAkoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ETGlobeNewswireCharlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Receives Two Design Wins with Tier-1 Network Infrastructure CustomerGlobeNewswireTier-1 Customer to Use High-Performance Akoustis XBAW® Filters for Two Wi-Fi 7 Fixed Wireless Access Enterprise and Home Gateway PlatformsCompany Has Received Orders to Support Production Ramp Throughout
2y agoAKTSAkoustis Secures Design Win and Volume Orders for Wi-Fi 7 Solution with Tier-1 Enterprise Class OEMGlobeNewswireTier-1 Customer to Use High-Performance Akoustis XBAW® Filters in 4X4 MU-MIMO Enterprise Router PlatformCompany Has Received Volume Orders to Facilitate Production Ramp in the Second Half of Calendar Year 2024
2y agoAKTSAkoustis Introduces Two New 2.4 GHz BAW RF Filters for Wi-Fi Automotive and Access Point ApplicationsGlobeNewswireNew High-Performance 2.4 GHz Channel 1-11 XBAW® Bandedge RF Filters for Improved Wi-Fi Range and Coexistence with LTEThe A10124 and A10324 is Currently Sampling and Slated for Production Second Half of Calendar Year
2y agoAKTSAkoustis to Attend the 36th Annual Roth Conference on March 17-19, 2024GlobeNewswireCharlotte, N.C., March 11, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis to Attend GOMACTech 2024 in Charleston from March 19-20GlobeNewswireCharlotte, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Reports Second Quarter FY24 ResultsGlobeNewswireQ2 Revenue Up 20% Year-Over-Year, In-Line with Prior Guidance Guiding Record Quarterly Revenue for the March Quarter—Up 18 to 25% SequentiallyGrowth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating
2y agoAKTSAkoustis Receives Wi-Fi 7 Design Win from Tier-1 US-Based CarrierGlobeNewswireTier-1 Customer to Use Akoustis' Next-Generation 5.5 and 6.5 GHz Wi-Fi 7 XBAW® Filters in 4x4 MIMO Router PlatformSecures Wi-Fi 7 Filter Orders to Support Production Ramp in September Quarter of Calendar Year
2y agoAKTSAkoustis Achieves Wi-Fi 7 Design Win and Volume Orders for Two New Programs from Current Tier-1 Enterprise Wi-Fi AP Solutions ProviderGlobeNewswireTier-1 Customer to Use Multiple Akoustis XBAW® Filters in 4X4 and 2X2 MU-MIMO Enterprise Access Point PlatformsHas Received Volume Orders to Facilitate Production Ramp in the Second Half of Calendar Year 2024
2y agoAKTSAkoustis to Webcast Q2FY24 Results on February 13 at 8:00 am ETGlobeNewswireCharlotte, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional SharesGlobeNewswireCharlotte, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Secures a wBMS Design Win with Tier-1 Automotive Product SupplierGlobeNewswireFirst BAW Design Win at a Tier-1 Automotive Customer in the Fast-Growing EV Market Segment Based on IC Reference Design by a Leading Semiconductor Supplier Production Expected to Ramp in the March Quarter of
2y agoAKTSAkoustis Announces Pricing of Public Offering of $10.0 Million of Common StockGlobeNewswireBoard Co-Chair, CEO, CPO, and Other Company Management and Employees Investing $1 Million Charlotte, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) ("Akoustis" or the
2y agoAKTSAkoustis Announces Proposed Public Offering of Common StockGlobeNewswireCharlotte, N.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Receives Wi-Fi 7 Design Win from Tier-1 Enterprise Wi-Fi AP ProviderGlobeNewswireSecond Tier-1 Customer to Use Multiple Akoustis 5 GHz and 6 GHz Wi-Fi 7 Filters for a 4X4 MU-MIMO AP PlatformHas Received Prototype Orders to Enable Production Ramp in the Second Half Calendar Year 2024 Charlotte,
2y agoAKTSAkoustis to Attend the 26th Annual Needham Growth Conference on January 16, 2024GlobeNewswireCharlotte, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis to Attend CES 2024 Conference in Las Vegas from January 9-12GlobeNewswireCharlotte, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSWi-Fi NOW Awards Akoustis and HPE Aruba Networking for Best Enterprise Wi-Fi SolutionGlobeNewswireCharlotte, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Receives Wi-Fi 6E Design Win from Tier-1 Consumer AP CustomerGlobeNewswireTier-1 Customer to Use Akoustis' 5 GHz and 6 GHz Tandem Wi-Fi 6E Filters for a 2X4 MU-MIMO Consumer AP PlatformSecures High-Volume Wi-Fi 6E Filter Orders to Support Production Ramp in March Quarter of Calendar
2y agoAKTSAkoustis Receives First Development Order from Leading Commercial Satellite Communications Company for Use of XBAW® Foundry ServicesGlobeNewswireNumber of Companies Utilizing XBAW® Foundry Services Increases to FourLaunch of Akoustis' XBAW® Synthesizer Software as part of Foundry ServicesFoundry Focused on 2 to 20 GHz in Commercial and Defense
2y agoAKTSAkoustis Awarded Phase 2 For DARPA COFFEE ProgramGlobeNewswireMulti-Year, Multi-Million Dollar Phase 2 Award for Development of High Frequency 2-18 GHz XBAW® Filter TechnologyAward Invests in Development of Akoustis' Single-Crystal and XP3F Filter TechnologiesNew
2y agoAKTSAkoustis to Attend the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023GlobeNewswireCharlotte, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF
2y agoAKTSAkoustis Technologies, Inc. (AKTS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAKTSAkoustis Reports First Quarter FY24 ResultsGlobeNewswireQ1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance Guiding Revenue Flat in December Quarter, then 18 to 25% Growth with Record Revenue Projected in March QuarterGrowth, Cost Savings
3y agoAKTSAkoustis Receives Purchase Order for Three BAW Filter Designs from 5G Mobile and Wi-Fi Router RF Front-End CustomerGlobeNewswireNew Designs Developed Using Akoustis' Proprietary XBAW Foundry ProcessCustomer Designed Filters to Target Wi-Fi 7 AP and China Mobile MarketsProduction Ramp Expected in First Half Calendar 2024 Charlotte, N.C.,